HOUSE DOCKET, NO. 1676        FILED ON: 1/19/2017

HOUSE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 710

The Commonwealth of Massachusetts

_________________

PRESENTED BY:

Cory Atkins

_________________

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to synthetic drugs.

_______________

PETITION OF:

HOUSE DOCKET, NO. 1676        FILED ON: 1/19/2017

HOUSE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 710

[SIMILAR MATTER FILED IN PREVIOUS SESSION
SEE HOUSE, NO. 4310 OF 2015-2016.]

The Commonwealth of Massachusetts

_______________

In the One Hundred and Ninetieth General Court
(2017-2018)

_______________

An Act relative to synthetic drugs.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:
 

SECTION 1. Section 1 of chapter 94C of the General Laws as appearing in the 2014 Official Edition is hereby amended by striking the words “controlled substance analogue” in lines 23-24 and inserting in place the words “synthetic drug.”

SECTION 2. Section 1 of chapter 94C is further amended by striking the definition for “Controlled substance analogue,” lines 26-52.

SECTION 3. Section 1 of chapter 94C is further amended by inserting the following definition at line 316:-

“Synthetic drug”,   a drug with properties and effects similar to a known hallucinogen or narcotic but having an altered chemical structure, including any substance within a structural group listed in “CLASS D” subsection (c) of section 31 of this chapter.

SECTION 4.  Section 31 of chapter 94C is further amended by adding to “CLASS D” at line 326:-

(c) Unless specifically excepted or unless listed in another class, any substance within the following structural groups:

1)Any compound containing an indole ring system with a substituent on the nitrogen atom and bearing an additional substituent at the 3-position of the indole ring system, with a linkage connecting the ring system to the substituent:

a)Where the linkage connecting the indole ring system to the substituent at its 3-position is any of the following: Alkyl, Carbonyl, Ester, Thione, Thioester, Amino, Alkylamino, Amido, Alkylamido

b)Where the substituent at the 3-position of the indole ring system is, disregarding the linkage, any of the following groups: Naphthyl, Quinolinyl, Adamantyl, Phenyl, Cycloalkyl (limited to clyclopropyl, clyclobutyl, cyclopentyl, or cyclohexyl), Biphenyl, Allcylamido (limited to ethylamido, propylamido, butanamido, or pentanamido), Benzyl, Carboxylic acid, Ester, Ether, Phenylpropylamido, Phenylopropylamino.

c)Whether or not the substituent at the 3-position of the indole ring system, disregarding the linkage, is further substituted to any extent.

d)Whether or not further substituted on the indole ring system to any extent.

2)Any compound containing an indazole ring system with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the indazole ring system, with a linkage connecting the ring system to the substituent:

a)Where the linkage connecting the indazole ring system to the substituent at its 3-position is any of the following: Alkyl, Carbonyl, Ester, Thione, Thioester, Amino, Alkylamino, Amido, Alkylamido

b)Where the substituent at the 3-position of the indazole ring system is, disregarding the linkage, any of the following groups: Naphthyl, Quinolinyl, Adamantyl, Phenyl, Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), Biphenyl, Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido), Benzyl, Carboxylic acid, Ester, Ether, Phenylpropylamido, Phenylopropylamino

c)Whether or not the substituent at the 3-position of the indazole ring system, disregarding the linkage, is further substituted to any extent.

d)Whether or not further substituted on the indazole ring system to any extent.

3)Any compound containing a pyrrole ring with a substituent on the nitrogen atom and bearing an additional substituent at the 3-position of the pyrrole ring, with a linkage connecting the ring to the substituent:

a)Where the linkage connecting the pyrrole ring to the substituent at its 3-position is any of the following: Alkyl, Carbonyl, Ester, Thione, Thioester, Amino, Alkylamino, Amido, Alkylamido

b)Where the substituent at the 3-position of the pyrrole ring is, disregarding the linkage, any of the following groups: Naphthyl, Quinolinyl, Adamantyl, Phenyl, Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), Biphenyl, Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido), Benzyl, Carboxylic acid, Ester, Ether, Phenylpropylamido, Phenylopropylamino

c)Whether or not the substituent at the 3-position of the pyrrole ring, disregarding the linkage, is further substituted to any extent.

d)Whether or not further substituted on the pyrrole ring to any extent.

4)Any compound containing a pyrazole ring with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the pyrazole ring with a linkage connecting the ring to the substituent:

a)Where the linkage connecting the pyrazole ring to the substituent at its 3-position is any of the following: Alkyl, Carbonyl, Ester, Thione, Thioester, Amino, Alkylamino, Amido, Alkylamido

b) Where the substituent at the 3-position of the pyrazole ring is, disregarding   the linkage, any of the following groups: Naphthyl, Quinolinyl, Adamantyl, Phenyl, Cyclopentyl, or cyclohexyl, Cycloalkyl (limited to cyclopropyl, cyclobutyl, or biphenyl), Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido), Benzyl, Carboxylic acid, Ester, Ether, Phenylpropylamido, Phenylopropylamino

c)Whether or not the substituent at the 3-position of the pyrazole ring, disregarding the linkage, is further substituted to any extent.

d)Whether or not further substituted on the pyrazole ring to any extent.

5)Any compound containing a pyrazole ring with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the pyrazole ring with a linkage connecting the ring to the substituent:

a)Where the linkage connecting the pyrazole ring to the substituent at its 3 position is any of the following: Alkyl, Carbonyl, Ester, Thione, Thioester, Amino, Alkylamino, Amido, Alkylamido

b)Where the substituent at the 3 position of the pyrazole ring is, disregarding the linkage, any of the following groups: Naphthyl, Quinolinyl, Adamantyl, Phenyl, Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), Biphenyl, Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido), Benzyl, Carboxylic acid, Ester, Ether, Phenylpropylamido, Phenylpropylamino

c)Whether or not the substituent at the 3 position of the pyrazole ring, disregarding the linkage, is further substituted to any extent.

d)Whether or not further substituted on the pyrazole ring to any extent.

6) Any compound containing a naphthalene ring system with a substituent on the 1 position carbon atom and bearing an additional substituent at the 4 position of the naphthalene ring system, with a linkage connecting the ring system to the substituent:

a)Where the linkage connecting the naphthalene ring system to the substituent at its 4 position is any of the following: Alkyl, Carbonyl, Ester, Thione, Thioester, Amino, Alkylamino, Amido, Alkylamido

b)Where the substituent at the 4 position of the naphthalene ring system is, disregarding the linkage, any of the following groups: Naphthyl, Quinolinyl, Adamantyl, Phenyl, Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), Biphenyl, Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido), Benzyl, Carboxylic acid, Ester, Ether, Phenylpropylamido, Phenylpropylamino

c)Whether or not the substituent at the 4 position of the naphthalene ring system, disregarding the linkage, is further substituted to any extent.

d)Whether or not further substituted on the naphthalene ring system to any extent.

7)Any compound containing a carbazole ring system with a substituent on the nitrogen atom and bearing an additional substituent at the 1, 2, or 3 position of the carbazole ring system, with a linkage connecting the ring system to the substituent:

a)Where the linkage connecting the carbazole ring system to the substituent at its 1, 2, or 3 position is any of the following: Alkyl, Carbonyl, Ester, Thione, Thioester, Amino, Alkylamino, Amido, Alkylamido

b)Where the substituent at the 1, 2, or 3 position of the carbazole ring system is, disregarding the linkage, any of the following groups: Naphthyl, Quinolinyl, Adamantyl, Phenyl, Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), Biphenyl, Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido), Benzyl, Carboxylic acid, Ester, Ether, Phenylpropylamido, Phenylpropylamino

c)Whether or not the substituent at the 1, 2, or 3 position of the carbazole ring system, disregarding the linkage, is further substituted to any extent.

d)Whether or not further substituted on the carbazole ring system to any extent.

8) Any substance which includes, but is not limited to the following:

a)QUCHIC/BB-22.

b)STS-135.

c)APICA/SDB-001.

d)ADBICA.

e)ADB-FUBINACA.

f)AB-001.

g)SDB-006.

h)EG-018.

i)CB-13.

    j) 5-chloro-UR-144.

    k) FUB-PB-22.

9) Any synthetic cathinone, which shall be defined as any of the following chemical structures, their salts, isomers and salts of isomers, whenever the existence of these is possible within the specific chemical designation, including any compound structurally derived from 2-aminopropanal by substitution at the 1-position with a monocyclic or fused polycyclic ring system, including compounds further modified by:

a)Substitution on the ring system to any extent (including, but not limited to alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents), whether or not further substituted in the ring system by other substituents; and/or

b)Substitution at the 3-position with a saturated or unsaturated hydrocarbon substituent; and/or

c)Mono- or di- substitution at the 2-amino nitrogen atom with saturated or unsaturated hydrocarbon groups, or inclusion of the 2-amino nitrogen atom in a cyclic structure, whether or not that cyclic structure contains any further substitutions; This term shall not include substances that are otherwise scheduled under the Controlled Substances Act: (e.g. cathinone, methcathinone, methylone, mephedrone, MDPV, diethylpropion, pyrovalerone), are FDA-approved pharmaceutical products (i.e. bupropion) or are FDA-approved research products.

10) Any synthetic psychoactive compound or substance which shall be defined as substances and their salts, isomers, and salts of isomers, wherever the existence of these is possible, within the following specific chemical designation:

a)2,5-dimethoxy-4-methyl-N-(2-methoxybenzyl)phenethylamine (also known as 25D-NBOMe).

b)2,5-dimethoxy-4-ethyl-N-(2-methoxybenzyl)phenethylamine (also known as 25E-NBOMe).

c)2,5-dimethoxy-4-nitro-N-(2-methoxybenzyl)phenethylamine (also known as 25N-NBOMe).

d)2,5-dimethoxy-4-n-propyl-N-(2-methoxybenzyl)phenethylamine (also known as 25P-NBOMe).

e)2,5-dimethoxy-4-ethylthio-N-(2-methoxybenzyl)phenethylamine (also known as 25T2-NBOMe).

f)2,5-dimethoxy-4-sec-propylthio-N-(2-methoxybenzyl)phenethylamine (also known as 25T4-NBOMe).

g)2,5-dimethoxy-4-n-propylthio-N-(2-methoxybenzyl)phenethylamine (also known as 25T7-NBOMe).

h)N-(2-methoxybenzyl)-3,4-dimethoxyamphetamine (also known as 34-DMA NBOMe).

i) 1-(1-Benzofuran-2-yl)propan-2-amine (also known as 2-APB).

j) 5-(2-aminopropyl)-2,3-dihydrobenzofuran (also known as 5-APDB).

k)) 2-(2-ethylaminopropyl)benzofuran (also known as 2-EAPB).

l) 1-(Benzofuran-5-yl)-N-methylpropan-2-amine (also known as 5-MAPB).

m) 3,4-dichloromethylphenidate.

n) 5,6-methylenedioxy-2-aminoindan (also known as 5,6-MDAI).

o) 4-hydroxy-diethyltryptamine (also known as 4-hydroxy-DET).

p) 4-methoxyphencyclidine (also known as 4-methoxy-PCP or methoxydine).

q) 3,4-dichloro-N-([1-(dimethylamino)cyclohexyl]methyl)benzamide (also known as AH-7921).

r) Benocyclidine (also known as BTCP).

s) Methoxetamine (also known as MXE).

t) 3-Methyl-6-[3-trifluoromethyl)phenyl]-1,2,4-triazolo[4,3-b]pyridazine (also known as CL218872).

u) 1-(1,2-diphenylethyl)piperidine (also known as diphenidine).

v) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (also known as MT-45).

w) (3-diethylamino-2,2-dimethylpropyl)-4-nitrobenzoate (also known as nitrocaine or nitracaine).

x) (E)-4-chloro-N-1(phenylethylpiperidin-2-ylidene)sulfonamide (also known as W-15).

y) (E)-4-chloro-N-(1-(4-nitrophenylethyl)piperidin-2-ylidene)sulfonamide (also known as W-18).

z) 4-fluoroamphetamine.

aa) 1-(thiophen-2-yl)-2-methylaminopropane (also known as methiopropamine).

11) This definition shall not include:

a)Endocannabinoids that are naturally found in the human body;

b)Delta-9 Tetrahydrocannabinol (THC) or other marijuana-derived cannabinoids, in the form of marinol, dronabinol, or another generic pharmaceutical equivalent, provided the medication has been issued as the result of a valid prescription; or

c)Any other drugs that have cannabinoid receptor activity that are currently approved by the United States Food and Drug Administration for medical use; or marijuana and extracts of marijuana authorized for therapeutic use.

SECTION 5. Section 31 of chapter 94C is further amended by adding to “CLASS D” the following additional subsections:-

(d) Any substance controlled in Schedule I of Title 21 of the Code of Federal Regulations Part 1308.11 or in Schedule II of Title 21 of the Code of Federal Regulations Part 1308.12, unless specifically excepted or unless listed in another class in this section.

(e) Public notice of this section shall be prepared by the Commissioner of the Department of Public Health and the Attorney General, and such notice shall be posted on the public websites of both the Department of Public Health and the Office of the Attorney General continuously for 180 days before the effective date of this act.